ITeos Therapeutics Inc (NAS:ITOS)
$ 18.03 -0.06 (-0.33%) Market Cap: 651.30 Mil Enterprise Value: 210.14 Mil PE Ratio: 0 PB Ratio: 1.20 GF Score: 40/100

Iteos Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 11:00PM GMT
Release Date Price: $10.86 (-4.15%)
Brian Cheng JPMorgan;Analyst

Good afternoon and thanks for joining us for another session at the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here. On stage, we have iTeos team. I'll pass the mic to iTeos for a short presentation, followed by a live audience Q&A. If you're joining us live, you can submit a question for the team through our conference portal. iTeos, the stage is yours. Michel?

Michel Detheux iTeos Therapeutics
Inc. - President & CEO

Thank you very much. Good afternoon, everyone, and welcome. I would like to thank you, JPMorgan, for hosting the conference and Brian for inviting us.

Before to start, I would like to spend a few minutes to describe what is iTeos. For the last decade, we have built an incredible expertise in tumor immunology that allow us to go above and beyond to understand how to create differentiated therapies to help people living with cancer. Today, we are very excited to start 2024 because we are into an incredible position with most milestone-driven year

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot